This map shows the geographic impact of A Ardizzoia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Ardizzoia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Ardizzoia more than expected).
This network shows the impact of papers produced by A Ardizzoia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Ardizzoia. The network helps show where A Ardizzoia may publish in the future.
Co-authorship network of co-authors of A Ardizzoia
This figure shows the co-authorship network connecting the top 25 collaborators of A Ardizzoia.
A scholar is included among the top collaborators of A Ardizzoia based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with A Ardizzoia. A Ardizzoia is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Cerea, Giulio, Massimo Vaghi, A Ardizzoia, et al.. (2003). Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.. PubMed. 23(2C). 1951–4.87 indexed citations
10.
Lissoni, P., Massimo Vaghi, Luca Fumagalli, et al.. (2002). Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.. PubMed. 22(2B). 1061–4.19 indexed citations
11.
Lissoni, Paolo, Elena Fumagalli, Fabio Malugani, et al.. (2002). Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.. PubMed. 15(2). 163–5.3 indexed citations
12.
Lissoni, Paolo, R Bucovec, Fabio Malugani, et al.. (2002). A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.. PubMed. 22(2B). 1131–4.19 indexed citations
13.
Lissoni, Paolo, Massimo Vaghi, A Ardizzoia, et al.. (2001). Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.. PubMed. 22(1). 27–9.13 indexed citations
Lissoni, Paolo, Sandro Barni, A Ardizzoia, et al.. (1994). Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.. PubMed. 7(4). 121–5.18 indexed citations
16.
Lissoni, Paolo, Franco Rovelli, Gabriele Tancini, et al.. (1993). Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer.. PubMed. 6(4). 113–5.5 indexed citations
17.
Lissoni, Paolo, Sandro Barni, Gabriele Tancini, et al.. (1993). [Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].. PubMed. 65(2). 123–8.1 indexed citations
18.
Ardizzoia, A, Paolo Lissoni, F Brivio, et al.. (1993). Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease.. PubMed. 6(3). 103–7.71 indexed citations
19.
Crispino, Sergio, Paolo Lissoni, A Ardizzoia, et al.. (1993). Effects of granulocyte-macrophage colony stimulating factor on cortisol, growth hormone, prolactin and melatonin in cancer patients (short communication).. PubMed. 6(4). 142–4.7 indexed citations
20.
Lissoni, Paolo, et al.. (1992). A clinical study of the pineal hormone melatonin in patients with growth hormone or prolactin secreting pituitary tumours.. PubMed. 1(7). 407–10.11 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.